Angiotensin-(1-7): New perspectives in atherosclerosis treatment

Journal of Geriatric Cardiology

Volumn 12, Issue 6, 2015, Pages 676-682

  Zhang, Feng ^a,b   Liu, Jun ^a   Li, Su Fang ^a   Song, Jun Xian ^a   Ren, Jing Yi ^a   Chen, Hong ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Angiotensin (1 7); Atherosclerosis; Endothelial function; Smooth muscle cell function

Indexed keywords

ANGIOTENSIN[1-7];

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIOSYNTHESIS; CELL MIGRATION; CELL PROLIFERATION; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; LIPID METABOLISM; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE CELL; VASOCONSTRICTION;

EID: 84953738612     PISSN: 16715411     EISSN: None     Source Type: Journal    
DOI: 10.11909/j.issn.1671-5411.2015.06.014     Document Type: Review

References (62)

1. Santos RA, Brosnihan KB, Chappell MC, et al. Converting enzyme activity and angiotensin metabolism in the dog brain-stem. Hypertension 1988; 11: 153-157.
2. Campagnole-Santos MJ, Diz DI, Santos RA, et al. Cardiovascular effects of angiotensin-(1-7) injected into the dorsal medulla of rats. Am J Physiol 1989; 257: H324-329.
3. Benter IF, Diz DI, Ferrario CM. Cardiovascular actions of angiotensin (1-7). Peptides 1993; 14: 679-684.
4. Ferreira AJ, Murca TM, Fraga-Silva RA, et al. New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis. Int J Hypertens 2012; 147825.
5. Bihl JC, Zhang C, Zhao Y, et al. Angiotensin-(1-7) counteracts the effects of Ang II on vascular smooth muscle cells, vascular remodeling and hemorrhagic stroke: Role of the NFκB inflammatory pathway. Vascul Pharmacol 2015; 73: 115-123.
6. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011; 17: 1410-1422.
7. Ferrario CM, Strawn WB. Role of the renin-angioten-sin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98: 121-128.
8. Keidar S, Kaplan M, Gamliel-Lazarovich A. ACE2 of the heart: From angiotensin I to angiotensin (1-7). Cardiovasc Res 2007; 73: 463-469.
9. Tikellis C, Bialkowski K, Pete J, et al. ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes 2008; 57: 1018-1025.
10. Greene LJ, Spadaro AC, Martins AR, et al. Brain endo-oli-gopeptidase B: a post-proline cleaving enzyme that inactivates angiotensin I and II. Hypertension 1982; 4: 178-184.
11. Grobe N, Weir NM, Leiva O, et al. Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry. Am J Physiol Cell Physiol 2013; 304: 945-953.
12. Laxton RC, Hu Y, Duchene J, et al. A role of matrix metallo-proteinase-8 in atherosclerosis. Circ Res 2009; 105: 921-929.
13. Santos RA, Simoes e Silva AC, Maric C, et al. Angio-tensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 2003; 100: 8258-8263.
14. Gironacci MM, Adamo HP, Corradi G, et al. Angiotensin (1-7) induces MAS receptor internalization. Hypertension 2011; 58: 176-181.
15. Zhang F, Ren J, Chan K, et al. Angiotensin-(1-7) regulates Angiotensin II-induced VCAM-1 expression on vascular en-dothelial cells. Biochem Biophys Res Commun 2013; 430: 642-646.
16. Anton L, Merrill DC, Neves LA, et al. Angiotensin-(1-7) inhibits in vitro endothelial cell tube formation in human umbilical vein endothelial cells through the AT(1-7) receptor. Endocrine 2007; 32: 212-218.
17. Liang B, Wang X, Zhang N, et al. Angiotensin-(1-7) Attenuates Angiotensin II-Induced ICAM-1, VCAM-1, and MCP-1 Expression via the MAS Receptor Through Suppression of P38 and NF-kappaB Pathways in HUVECs. Cell Physiol Biochem 2015; 35: 2472-2482.
18. Stegbauer J, Potthoff SA, Quack I, et al. Chronic treatment with angiotensin-(1-7) improves renal endothelial dysfunction in apolipoproteinE-deficient mice. Br J Pharmacol 2011; 163: 974-983.
19. Durand MJ, Raffai G, Weinberg BD, et al. Angiotensin-(1-7) and low-dose angiotensin II infusion reverse salt-induced en-dothelial dysfunction via different mechanisms in rat middle cerebral arteries. Am J Physiol Heart Circ Physiol 2010; 299: 1024-1033.
20. Raffai G, Durand MJ, Lombard JH. Acute and chronic angio-tensin-(1-7) restores vasodilation and reduces oxidative stress in mesenteric arteries of salt-fed rats. Am J Physiol Heart Circ Physiol 2011; 301: 1341-1352.
21. Langeveld BE, Henning RH, de Smet BJ, et al. Rescue of arterial function by angiotensin-(1-7): towards improvement of endothelial function by drug-eluting stents. Neth Heart J 2008; 16: 291-292.
22. Wang Y, Qian C, Roks AJ, et al. Circulating rather than cardiac angiotensin-(1-7) stimulates cardioprotection after myo-cardial infarction. Circ Heart Fail 2010; 3: 286-293.
23. Seva Pessoa B, Becher PM, Van Veghel R, et al. Effect of a stable Angiotensin-(1-7) analogue on progenitor cell recruitment and cardiovascular function post myocardial infarction. J Am Heart Assoc 2015; 4.
24. Kucharewicz I, Pawlak R, Matys T, et al. Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). Hypertension 2002; 40: 774-779.
25. Fraga-Silva RA, Costa-Fraga FP, De Sousa FB, et al. An orally active formulation of angiotensin-(1-7) produces an an-tithrombotic effect. Clinics (Sao Paulo) 2011; 66: 837-841.
26. Soto-Pantoja DR, Menon J, Gallagher PE, et al. Angio-tensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol Cancer Ther 2009; 8: 1676-1683.
27. Freeman EJ, Chisolm GM, Ferrario CM, et al. Angio-tensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 1996; 28: 104-108.
28. Zhang F, Hu Y, Xu Q, et al. Different effects of angiotensin II and angiotensin-(1-7) on vascular smooth muscle cell proliferation and migration. PLoS One 2010; 5: e12323.
29. Langeveld B, van Gilst WH, Tio RA, et al. Angiotensin-(1-7) attenuates neointimal formation after stent implantation in the rat. Hypertension 2005; 45: 138-141.
30. Strawn WB, Ferrario CM, Tallant EA. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 1999; 33: 207-211.
31. Zeng W, Chen W, Leng X, et al. Chronic angiotensin-(1-7) administration improves vascular remodeling after angioplasty through the regulation of the TGF-beta/Smad signaling pathway in rabbits. Biochem Biophys Res Commun 2009; 389: 138-144.
32. Pan CH, Wen CH, Lin CS. Interplay of angiotensin II and angiotensin(1-7) in the regulation of matrix metalloprotei-nases of human cardiocytes. Exp Physiol 2008; 93: 599-612.
33. Johnson C, Galis ZS. Matrix metalloproteinase-2 and-9 differentially regulate smooth muscle cell migration and cellmediated collagen organization. Arterioscler Thromb Vasc Biol 2004; 24: 54-60.
34. Clark MA, Diz DI, Tallant EA. Angiotensin-(1-7) downregu-lates the angiotensin II type 1 receptor in vascular smooth muscle cells. Hypertension 2001; 37: 1141-1146.
35. Santos SH, Braga JF, Mario EG, et al. Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1-7). Arterioscler Thromb Vasc Biol 2010; 30: 953-961.
36. Feltenberger JD, Andrade JM, Paraiso A, et al. Oral formulation of angiotensin-(1-7) improves lipid metabolism and prevents high-fat diet-induced hepatic steatosis and inflammation in mice. Hypertension 2013; 62: 324-330.
37. Santos SH, Fernandes LR, Mario EG, et al. Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 2008; 57: 340-347.
38. Silva AR, Aguilar EC, Alvarez-Leite JI, et al. Mas receptor deficiency is associated with worsening of lipid profile and severe hepatic steatosis in ApoE-knockout mice. Am J Physiol Regul Integr Comp Physiol 2013; 305: R1323-R1330.
39. Suski M, Gebska A, Olszanecki R, et al. Influence of atorvas-tatin on angiotensin I metabolism in resting and TNF-alpha-activated rat vascular smooth muscle cells. J Renin Angio-tensin Aldosterone Syst 2014; 15: 378-383.
40. Li YH, Wang QX, Zhou JW, et al. Effects of rosuvastatin on expression of angiotensin-converting enzyme 2 after vascular balloon injury in rats. J Geriatr Cardiol 2013; 10: 151-158.
41. Schindler C, Guenther K, Hermann C, et al. Statin treatment in hypercholesterolemic men does not attenuate angiotensin II-induced venoconstriction. PLoS One 2014; 9: e103909.
42. Schindler C, Brosnihan KB, Ferrario CM, et al. Comparison of inhibitory effects of irbesartan and atorvastatin treatment on the renin angiotensin system (RAS) in veins: a randomized double-blind crossover trial in healthy subjects. J Clin Pharmacol 2007; 47: 112-120.
43. Yang JM, Dong M, Meng X, et al. Angiotensin-(1-7) dose-dependently inhibits atherosclerotic lesion formation and enhances plaque stability by targeting vascular cells. Arterio-scler Thromb Vasc Biol 2013; 33: 1978-1985.
44. Fraga-Silva RA, Savergnini SQ, Montecucco F, et al. Treatment with Angiotensin-(1-7) reduces inflammation in carotid atherosclerotic plaques. Thromb Haemost 2014; 111: 736-747.
45. Yang J, Sun Y, Dong M, et al. Comparison of angio-tensin-(1-7), losartan and their combination on atherosclerotic plaque formation in apolipoprotein E knockout mice. Atherosclerosis 2015; 240: 544-549.
46. Thatcher SE, Zhang X, Howatt DA, et al. Angiotensin-con-verting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipopro-tein receptor-/-mice. Arterioscler Thromb Vasc Biol 2011; 31: 758-765.
47. Zhang YH, Dong XF, Hao QQ, et al. ACE2 and Ang-(1-7) protect endothelial cell function and prevent early atherosclerosis by inhibiting inflammatory response. Inflamm Res 2015; 64: 253-260.
48. Dong B, Zhang C, Feng JB, et al. Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2008; 28: 1270-1276.
49. Alsaadon H, Kruzliak P, Smardencas A, et al. Increased aortic intimal proliferation due to MasR deletion in vitro. Int J Exp Pathol 2015; 96: 183-187.
50. Toton-Zuranska J, Gajda M, Pyka-Fosciak G, et al. AVE 0991-angiotensin-(1-7) receptor agonist, inhibits atherogenesis in apoE-knockout mice. J Physiol Pharmacol 2010; 61: 181-183.
51. Jawien J, Toton-Zuranska J, Gajda M, et al. Angiotensin-(1-7) receptor Mas agonist ameliorates progress of atherosclerosis in apoE-knockout mice. J Physiol Pharmacol 2012; 63: 77-85.
52. Jawien J, Toton-Zuranska J, Kus K, et al. The effect of AVE 0991, nebivolol and doxycycline on inflammatory mediators in an apoE-knockout mouse model of atherosclerosis. Med Sci Monit 2012; 18: 389-393.
53. Olszanecki R, Suski M, Gebska A, et al. The influence of angiotensin-(1-7) peptidomimetic (AVE 0991) and nebivolol on angiotensin I metabolism in aorta of apoE-knockout mice. J Physiol Pharmacol 2013; 64: 317-320.
54. Yang J, Yang X, Meng X, et al. Endogenous activated angio-tensin-(1-7) plays a protective effect against atherosclerotic plaques unstability in high fat diet fed ApoE knockout mice. Int J Cardiol 2015; 184: 645-652.
55. Peltonen T, Napankangas J, Ohtonen P, et al. (Pro) renin receptors and angiotensin converting enzyme 2/angiotensin-(1-7)/Mas receptor axis in human aortic valve stenosis. Atherosclerosis 2011; 216: 35-43.
56. Marques FD, Ferreira AJ, Sinisterra RD, et al. An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats. Hypertension 2011; 57: 477-483.
57. Bertagnolli M, Casali KR, De Sousa FB, et al. An orally active angiotensin-(1-7) inclusion compound and exercise training produce similar cardiovascular effects in spontaneously hypertensive rats. Peptides 2014; 51: 65-73.
58. de Vries L, Reitzema-Klein CE, Meter-Arkema A, et al. Oral and pulmonary delivery of thioether-bridged angio-tensin-(1-7). Peptides 2010; 31: 893-898.
59. Kluskens LD, Nelemans SA, Rink R, et al. Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog. J Pharmacol Exp Ther 2009; 328: 849-854.
60. Durik M, van Veghel R, Kuipers A, et al. The effect of the thioether-bridged, stabilized Angiotensin-(1-7) analogue cyclic ang-(1-7) on cardiac remodeling and endothelial function in rats with myocardial infarction. Int J Hypertens 2012; 2012: 536426.
61. Frezard F, Silva-Barcellos NM, Dos Santos RA. A novel approach based on nanotechnology for investigating the chronic actions of short-lived peptides in specific sites of the brain. Regul Pept 2007; 138: 59-65.
62. Silva-Barcellos NM, Caligiorne S, dos Santos RA, et al. Site-specific microinjection of liposomes into the brain for local infusion of a short-lived peptide. J Control Release 2004; 95: 301-307.